Genome editing by CRISPR/Cas9 might disrupt the anti-cancer p53 protein function

The two studies published Monday are a potential game-changer for companies pursuing CRISPR-based therapies, but as one researcher said, "I don't think it's a deal-breaker."

About Robert Zinn

Robert Zinn, M.D., Ph.D. is a medical doctor, physician, and web entrepreneur, who, for over 15 years was employed by academic and research institutions and focused his clinical practices on very specialized patient populations, such as those with rare genetic diseases or rare cancers. He shares his knowledge through his website,

View all posts by Robert Zinn →